CD74′s prognostic value varies by tumor type: favorable in immune-inflamed cancers such as melanoma and HCC, but adverse in malignancies driven by MIF-mediated survival signals such as lymphomas and PDAC. This evidence concerns the gene CD74 and neoplasm.